Batten disease (CLN7 / MFSD8)

Overview

Batten disease is a group of rare, inherited neurological conditions, often referred to as neuronal ceroid lipofuscinoses (NCLs). These are progressive disorders that primarily affect the brain and eyes, leading to significant deterioration over time. The 'CLN7' subtype of Batten disease, also known as variant late-infantile NCL, typically becomes apparent in childhood, usually between ages 2 and 7 years [PMID:32060133]. Affected individuals experience a range of symptoms that worsen as they age.

The condition involves the accumulation of a fatty-like substance, called lipofuscin, within the lysosomes of cells throughout the body, particularly in the brain and retina. Lysosomes are cellular compartments responsible for breaking down and recycling waste products. When they do not function correctly, these materials build up, leading to cell damage and impaired function, which causes the observed symptoms of Batten disease.

Symptoms & clinical features

The initial symptoms of CLN7 Batten disease often include progressive vision loss, which can eventually lead to blindness. This vision impairment may be one of the earliest noticeable signs [PMID:31724623]. As the condition progresses, individuals often develop epilepsy, characterised by recurrent seizures that can vary in type and severity.

Over time, other neurological symptoms become apparent. These can include a decline in motor skills, leading to difficulties with coordination, balance, and walking. Speech development may be delayed or speech might regress. Cognitive abilities are also affected, resulting in learning difficulties and intellectual decline. Behavioural changes, such as irritability or anxiety, can also occur. The progression and severity of these symptoms can vary between individuals.

Video: Genetics 101

Affected organs

Batten disease (CLN7) primarily affects the central nervous system and the eyes. The brain undergoes progressive degeneration, leading to the neurological symptoms observed. Nerve cells (neurons) are particularly vulnerable to the accumulation of waste materials, which impairs their function and ultimately leads to their loss.

The retina, the light-sensitive tissue at the back of the eye, is also significantly affected. The build-up of lipofuscin in retinal cells disrupts their normal function, causing the progressive vision loss that is a hallmark of the condition. Other organs, such as the heart and muscles, can also be affected in some forms of Batten disease, although the primary impact of CLN7 is on the brain and eyes.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

CLN7 Batten disease is a severe and progressive condition. Symptoms typically begin in early to mid-childhood, usually between 2 and 7 years of age. The progression of the disease varies, but it generally leads to significant disability over time. Individuals often experience profound vision loss, severe neurological impairment including uncontrolled seizures, and a decline in cognitive and motor functions [PMID:32060133].

While the exact prevalence is not well established, Batten disease, as a group, is considered rare. The overall prognosis is generally poor due to the progressive neurodegeneration. Managing symptoms and providing supportive care are crucial aspects of care for individuals and their families.

Genetic causes

Batten disease (CLN7) is caused by genetic changes in the MFSD8 gene. The MFSD8 gene provides instructions for making a protein called MFSD8, which is thought to be involved in the transport of molecules across lysosomal membranes. Lysosomes are vital structures within cells that break down and recycle waste products.

Pathogenic variants (also known as mutations) in the MFSD8 gene lead to a dysfunctional MFSD8 protein. When this protein does not work correctly, there is a build-up of specific fatty-like substances, known as lipofuscins, within the lysosomes of cells. This accumulation is particularly damaging to nerve cells in the brain and the cells of the retina, leading to the characteristic neurodegeneration and vision loss seen in Batten disease (CLN7).

• MFSD8
  major facilitator superfamily domain containing 8
  The MFSD8 gene provides instructions for a protein thought to be involved in transporting molecules across lysosomal membranes, playing a role in cellular waste recycling.

Inheritance pattern

Batten disease (CLN7) is inherited in an autosomal recessive pattern. This means that a child must inherit two altered copies of the MFSD8 gene - one from each parent - to develop the condition.

Parents who each carry one copy of the altered gene are known as carriers. Carriers typically do not show symptoms of the condition themselves because they have one working copy of the gene, which is usually sufficient. For each child born to two carrier parents, there is a 25% chance the child will inherit two altered copies and develop the condition, a 50% chance the child will be a carrier like their parents, and a 25% chance the child will inherit two working copies of the gene and not be a carrier or have the condition.

Diagnosis & testing

Diagnosing Batten disease (CLN7) typically begins with a clinical evaluation based on the observable symptoms, such as progressive vision loss, seizures, and developmental regression. A paediatric neurologist or ophthalmologist might be the first specialist involved. Further investigations can include electroretinography (ERG) to assess retinal function, and brain imaging like MRI, which may show brain atrophy.

A definitive diagnosis is confirmed through genetic testing, which looks for pathogenic variants in the MFSD8 gene. This testing is available through the NHS Genomic Medicine Service (GMS) and would typically be requested by a clinical genetics specialist following a referral. The relevant NHS Genomic Test Directory R-code for neuronal ceroid lipofuscinosis genetic testing (which includes MFSD8) is R385. Genetic counsellors can explain the testing process and implications.

Management & lifestyle

While there is currently no cure for Batten disease (CLN7), management focuses on supportive care and symptom control to improve quality of life. This involves a multidisciplinary team approach within the NHS, including neurologists, ophthalmologists, physiotherapists, occupational therapists, speech and language therapists, and palliative care specialists.

Medications may be prescribed to help manage seizures and other neurological symptoms. Regular physiotherapy and occupational therapy can help maintain mobility and functional abilities for as long as possible. Special educational support is often required due to cognitive decline. Regular eye examinations are important for monitoring vision. Genetic counsellors can provide valuable support and information to families, helping them understand the condition and plan for future care. Research into new therapeutic approaches is ongoing.

UK care pathway

In the UK, suspected cases of rare inherited conditions like Batten disease are typically referred to specialist paediatric services or clinical genetics centres. If clinical suspicion is high, the NHS Genomic Medicine Service (GMS) provides diagnostic genetic testing, following a referral from a specialist clinician. Genetic counsellors play a key role in explaining the genetic basis of the condition, inheritance patterns, and the implications for families. The NHS Genomic Test Directory uses R-codes, such as R385, to guide specialist clinicians on appropriate genetic tests.

Related conditions

Batten disease (CLN7) is one of several forms of neuronal ceroid lipofuscinosis (NCL). Different types of NCL are caused by pathogenic variants in different CLN genes (e.g., CLN1, CLN2, CLN3, CLN4, CLN5, CLN6, CLN8, CLN10, etc.), each presenting with varying ages of onset and specific symptom profiles. While they all share the common feature of lipofuscin accumulation and progressive neurodegeneration, the specific gene involved dictates the precise clinical presentation. Genetic testing helps to differentiate between these various forms of NCL.

Frequently asked questions